Key Takeaways The EC approved Gileads lenacapavir, branded Yeytuo, as twice-yearly HIV prevention for at-risk groups.Approval followed accelerated EMA review, CHMP backing, and PURPOSE 1 and 2 trial data.Lenacapavir strengthens Gileads HIV portfolio as Truvada faces generic competition in prevention.Gilead Sciences, Inc. ((GILD) announced that the European Commission (“EC”) has granted marketing authorization to HIV prevention drug lenacapavir, under the brand name Yeytuo.The EC approved lenacapavir, GILD’s ...